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Epigenetic research involves examining the mitotically heritable processes that regulate
gene expression, independent of changes in the DNA sequence. Recent technical
advances such as whole-genome bisulfite sequencing and affordable epigenomic array-
based technologies, allow researchers to measure epigenetic profiles of large cohorts
at a genome-wide level, generating comprehensive high-dimensional datasets that may
contain important information for disease development and treatment opportunities. The
epigenomic profile for a certain disease is often a result of the complex interplay between
multiple genetic and environmental factors, which poses an enormous challenge to
visualize and interpret these data. Furthermore, due to the dynamic nature of the
epigenome, it is critical to determine causal relationships from the many correlated
associations. In this review we provide an overview of recent data analysis approaches
to integrate various omics layers to understand epigenetic mechanisms of complex
diseases, such as obesity and cancer. We discuss the following topics: (i) advantages
and limitations of major epigenetic profiling techniques, (ii) resources for standardization,
annotation and harmonization of epigenetic data, and (iii) statistical methods and
machine learning methods for establishing data-driven hypotheses of key regulatory
mechanisms. Finally, we discuss the future directions for data integration that shall
facilitate the discovery of epigenetic-based biomarkers and therapies.
Keywords: epigenetics, data integration, functional annotation, drug discovery, data resources, profiling
techniques
INTRODUCTION
Complex diseases and traits have a genetic background, yet the final phenotypic outcome largely
depends on an individual’s environment and lifestyle, and genomic studies have thus far explained
only a small fraction of the inherited risk of many complex diseases (Eichler et al., 2010). This
missing heritability may in part be explained by the contribution of epigenetic variation to complex
diseases. Moreover, the majority of genetic variants associated with a disease risk are located at
non-coding regions of the genome, suggesting that these SNPs point to genomic regions with
a downstream regulatory role. It is well-established that cells regulate gene expression during
multiple stages of transcription and translation, predominantly through chromatin packaging
(Holliday, 2006). Chromatin is a complex of DNA and DNA binding proteins that control the
packaging of DNA and thereby affect the access of transcription factors to the regulatory regions
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of genes. This process is regulated by two epigenetic mechanisms:
dynamic DNA methylation and post-translational modifications
of DNA binding histone proteins.
DNA methylation plays an important role in silencing tissue-
specific genes, imprinted genes and repetitive elements (Walsh
et al., 1998; Fouse et al., 2008). DNA methylation in human
cells occurs predominantly at the cytosine of a cytosine-guanine
pair (CpG dinucleotide), where a methyl group is covalently
attached to the carbon 5 position. In the human genome there
are approximately 28 million CpG dinucleotides, accounting for
1% of the whole genome. Of these, 60 to 90% are methylated,
while the majority of unmethylated sites cluster non-randomly
in regions called CpG islands (CGIs). CGIs co-localize to the
promoter region of up to 70% of human genes (Illingworth
and Bird, 2009). In general, unmethylated CGIs are associated
with transcriptionally permissive chromatin and gene expression.
During normal development and in certain disease states,
particularly in cancer, these CGIs can become methylated, leading
to inhibition of transcription factor binding and gene repression.
In addition to DNA methylation (5mC), DNA
hydroxymethylation (5hmC) is another essential epigenetic
modification in cells. Hydroxymethylation is the primary
product of the oxidation of 5-methylcytosine by the ten-eleven
translocation (TET) enzymes. In this process methylated
cytosine (5mC) is first oxidized into 5-hydroxymethylcytosine
(5hmC), then to 5-formylcytosine and to 5-carboxylcytosine
(5caC). These are removed by thymine DNA glycosylase and
replaced by unmethylated cytosine by base excision repair.
However, hydroxymethylation is not merely an intermediate of
the dynamic demethylation process but actually a temporarily
stable epigenetic modification of DNA (Globisch et al., 2010).
Hydroxymethylated cytosines are enriched at the promoters and
enhancers of developmental genes, and they correlate positively
with gene expression during cell lineage commitment in early
development. In addition, hydroxymethylation is present in
gene bodies of actively transcribed genes (Colquitt et al., 2013;
Tsagaratou et al., 2014; Nestor et al., 2016). Hydroxymethylation
is less abundant than DNA methylation, and its abundance
varies between tissues and cell types. It is more abundant
in embryonic stem cells (Ito et al., 2010), and human brain
tissue (0.67%), kidney (0.38%), colon (0.45%), rectum (0.57%),
and liver (0.46%), while low or very low in human lung,
breast and placenta (Li and Liu, 2011). The abundance of
hydroxymethylation seems to be inversely correlated with
the proliferation rate of a cell (Kriaucionis and Heintz, 2009;
Bachman et al., 2014). The dynamic interplay between DNA
methylation and hydroxymethylation is presumably important
for maintaining normal gene expression patterns in a cell,
however, the causes and consequences of the imbalance between
these two DNA modifications is still to be understood.
In contrast to DNA methylation and hydroxymethylation,
which are set de novo at early embryogenesis and maintained
during DNA replication, histone modifications are post-
translational changes. They act to remodel the chromatin
structure and regulate gene expression through chromatin
accessibility (ENCODE Project Consortium, 2012). Histone
modifications are the largest category of chromatin modifications
identified so far, with 15 known chemical modifications at
more than 130 sites on 5 canonical histones and on around
30 histone variants. Specific histone modification patterns
often correlate with known functional genomic elements. For
example, H3K9me3 and H3K27me3 are associated with inactive
promoters; while H3K4me3 and H3K27ac are shown to be
enriched in active enhancers and promoters (Karlic et al., 2010;
Zhou V.W. et al., 2011). However, the theoretical number
of all possible histone – modification combinations is huge,
particularly when compared to the extremely limited knowledge
on their functional roles.
An additional layer of epigenetic regulation is derived from
non-coding RNA (ncRNA), which is transcribed from DNA
but not translated into protein. NcRNA ranges from very small
22 nucleotide microRNA molecules (miRNA), to transcripts
longer than 200 nucleotides (lncRNA). NcRNAs play a role
in translation, splicing, DNA replication and gene regulation,
particularly through miRNA directed downregulation of
gene expression (Valencia-Sanchez et al., 2006). NcRNAs are
most widely studied in the context of cancer, where they
have been identified in the tumor suppressor or oncogenic
processes of all major cancers (Anastasiadou et al., 2018).
The techniques for measuring ncRNA are similar to other
transcriptomic techniques, predominantly involving deep
sequencing approaches (Veneziano et al., 2016). In recent years
it has become apparent that there is a coordinated interaction
between ncRNA and other epigenetic marks, the extent of which
is yet to be fully realized (Ferreira and Esteller, 2018). The
discovery of more than 100 post-transcriptional modifications to
ncRNA, such as methylated adenines and cytosines, is providing
further insight into the interaction between these different
epigenetic layers (Romano et al., 2018). For the latest advances
in the ncRNA biology, we refer the reader to the special series in
Nature Reviews Genetics, January 1st 20181.
DNA methylation (referring to both 5mC and 5hmC from
here on), histone modifications and ncRNA respond to genetic
and environmental effects and thereby alter gene expression,
providing biological mechanisms for the development of
common diseases. Therefore, epigenetic mechanisms are key
to understanding disease progression and discovering new
treatment targets (Lord and Cruchaga, 2014). As one of the
more recent omics fields, epigenomics has experienced rapid
growth in the past decade, providing novel insights to many
areas of cell biology. Recent developments in microarray
technology have made the generation of genome-wide epigenetic
data feasible in large populations (Pidsley et al., 2016).
As such, epigenome-wide association studies (EWASs) have
become an important component of omics-driven approaches
to investigate the origin of common human traits and diseases
(Lappalainen and Greally, 2017).
Despite the tremendous potential to improve our
understanding of disease progression and treatment, epigenetics
has yet to become fully utilized in clinical applications. Similar
to transcriptomics, epigenetic profiles are continuous, dynamic
and tissue-specific. As ever more epigenetic data are generated
1https://www.nature.com/collections/sqtqxdnvdz
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with advances in high-throughput sequencing and microarray
technologies, the challenges now become developing data
analysis approaches to facilitate the identification of coordinated
epigenetic changes and interpretation of their functional
consequences in normal development and disease. For example,
an effective data annotation protocol is needed for a community-
driven data standardization to improve the replicability of
epigenetic findings (Carter et al., 2017). In particular, the
variation in epigenetics profiles at different time points is
yet to be established as a control for the reference in normal
populations. Partly due to the lack of appropriate and efficient
computational methods, the majority of existing studies focus on
a single epigenetic mark in isolation, although the interactions
of multiple marks and genotypes exist in vivo (Davila-Velderrain
et al., 2015). To realize the full potential offered by epigenetics, an
interdisciplinary research community is needed to foster effective
and robust data integration strategies for combining epigenetics
data with other omics data (Figure 1).
In the following sections we will review the recent advances in
computational methods and applications for epigenomic analysis
and discovery, ranging from databases and software tools for
statistical analysis to data integration techniques for functional
annotation. We will start by comparing the common epigenomic
profiling technologies, before moving on to data annotation
and standardization models. We then provide an overview
of various data sources leveraged in epigenetic studies and
their applications. We describe statistical and machine learning
methods to pinpoint epigenetic modifications driving disease,
and provide a list of software tools capable of implementing these
methods, as well as databases containing epigenomic and other
omics data. This catalog provides a comprehensive and practical
resource to build data-driven hypotheses for analyzing the
functional consequences of epigenetic marks. Finally, we provide
representative examples of profiling epigenetics in disease states
and its significance in biomarker and drug discovery.
FIGURE 1 | The pillars to understanding the functional impact of epigenetics
data. The epigenetic links need to be made with sequence variants in genetics
as well as changes in transcriptomics. Understanding the impact of
epigenetics on intermediate phenotypes for example metabolomics and
proteomics may ultimately help explain the disease etiology and help drug
discovery. GWASs, genome-wide association studies; EWASs, epigenome
wide association studies; meQTL, methylation quantitative trait loci; eQTL,
expression quantitative trait loci; TWAS, transcriptome-wide association study.
EPIGENETIC PROFILING TECHNIQUES
Epigenetic analysis techniques can be broadly classified
as typing, involving a small number of loci across many
samples, or profiling that can be extended to epigenome-
wide analysis. The end-point measurements from these
methods often reflect a proportion or ratio of chromatin
with epigenetic marks compared to the total chromatin.
Within these categories, various sequencing, microarray and
antibody based methodologies are employed to examine the
different aspects of epigenetic regulation, including DNA
methylation, chromatin accessibility and histone modifications.
Epigenetic data generated from these techniques require
different pre-processing steps depending on the methodology
employed. For example, array-based DNA methylation analysis
requires extensive within and between array normalization,
preprocessing and integration across platforms (Fortin et al.,
2017), while bisulfite sequencing can be processed with a
relatively standardized sequence trimming and alignment
pipeline (Wreczycka et al., 2017). Further complications include
the feasibility of using epigenetic profiles derived from blood
as a proxy for other less accessible tissue types (Houseman
et al., 2015), and controlling for tumor purity in cancer studies
(Zheng et al., 2017). Here, we summarize the most common
epigenetic profiling techniques and compare their advantages




Unlike the human genome, the epigenome varies across
different cell types and over time. Due to recent efforts
in big data consortia, such as the Encyclopedia of DNA
Elements (ENCODE) (Davis et al., 2018) and the International
Human Epigenome Consortium (IHEC) (Bujold et al., 2016),
genome-wide epigenetic reference datasets are now publically
available for different cell lineages, tissues, and diseases.
Within IHEC, standardization of sample preparation and
assay protocols have been benchmarked and implemented
across multiple centers, that have been collected from
seven international consortia including ENCODE, NIH
Roadmap (Bernstein et al., 2010), Blueprint (Martens and
Stunnenberg, 2013) and others across Europe, North America,
and Asia. Furthermore, efficient data portal infrastructure
has provided powerful tools for interactive exploration
and annotation of the resulting datasets at a genome-
wide scale, encompassing over 800 reference epigenomes
for different tissues and conditions. Such a community-
driven profiling effort has provided rich resources and
tools for future epigenetic data mining and functional
annotation. More recently, these datasets have been made
available via the Human Epigenome Browser (Zhou X.
et al., 2011), providing the visualization tools similar to
the UCSC Genome Browser (Kent et al., 2002). Here, we
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list the common data repositories and their visualization
tools (Table 3).
To facilitate the sharing of epigenomic data between
different studies, standardization of sample preparation and assay
protocols is required. While there are existing recommendations
for reporting the minimal information to annotate omics studies
such as MIAME for gene expression data and MIAPE for
proteomics data, the consensus for the annotation protocol
for epigenetics data has yet to be defined. This is partly
due to the versatile techniques for various epigenetic features
TABLE 1 | Summary of major profiling techniques for DNA methylation.
Technique Method Advantages Limitations
Whole-Genome Bisulfite Sequencing
(WGBS)








enzymes digest DNA, enriching for
CpG regions
Cheaper than WGBS with relatively high
coverage
Enzymatic digestion covers most but
not all CpG sites
Pyrosequencing DNA is bisulfite converted, amplified,
with the ratio of C/T nucleotides
measured






Methylated DNA is enriched by
immunoprecipitation followed by
sequencing or microarray analysis
Random fragmentation by sonication
avoids restriction enzyme bias





Unmethylated DNA is restriction
enzyme digested while methylated DNA
is amplified
No bisulfite conversion bias DNA may be partially digested, limited
coverage
Combined Bisulfite Restriction Analysis
(COBRA)
Bisulfite converted DNA is amplified
and restriction enzyme digested
Simple, fast, inexpensive, works on
FFPE-treated DNA
DNA may be partially digested, limited
coverage
Methylation Specific PCR Bisulfite converted DNA is amplified
with methylation specific primers
Simple and inexpensive Purely qualitative
High Resolution Melt Analysis (HRM) Bisulfite converted DNA is amplified by
q-PCR
Most sensitive method for determining
methylation at a specific region
Single base resolution not possible
Illumina MethylationEPIC BeadChip
Microarray (previously 450k, 27k)
Bisulfite (or oxidized + bisulfite)
converted DNA is interrogated on a
microarray chip
Relatively simple and inexpensive.
Extremely popular
Data has limited coverage and requires
pre-processing
Global DNA Methylation Methods include LINE1, Alu, LUMA,
HPLC-UV




5hmC is protected then oxidized to
5caC then uracil by TET
Differentiation between 5mC and 5hmC
at single base resolution
Sensitivity and specificity depends on
sequencing depth
Oxidative Bisulfite Sequencing (OxBis) DNA is oxidized then bisulfite converted
to 5fC and subsequently uracil
Quantitative genome-wide coverage Bias to regions of low 5mC. Must be





enzymes discriminate between 5hmC
and 5mC
Genome-wide, single nucleotide
resolution. Very low DNA input required
Not yet extensively tested
Hydroxymethylated DNA
Immunoprecipitation (hMeDIP)
Immunoprecipitation and sequencing of
hydroxymethylated DNA
Simple and inexpensive Only semi quantitative and bias to
regions of low 5hmC
TABLE 2 | Summary of major profiling techniques for Chromatin Accessibility and Histone modifications.
Technique Method Advantages Limitations
Chromatin Immunoprecipitation (ChIP) Couples highly specific antibodies for
DNA-binding proteins with sequencing,
microarrays or PCR
Detect DNA associated proteins and
histone modifications
Requires intact cells and chromatin
Digital DNase Enzymes digest nuclease-accessible
regions, indicating open chromatin
Maps both nucleosomes and
non-histone proteins




Maps both DNA methylation and
nucleosomes at high resolution




Measures chromatin accessibility based
on Tn5 transposase activity. Maps
nucleosomes and non-histone proteins
Simple, fast, low input of cells with
single nucleotide resolution
Distance between binding sites may
bias results
Chromosome Conformation Capture
(3C, 4C, 5C, Hi-C)
Assess spatial organization of
chromatin in a cell
Various modified versions Often lack genome-wide, single
nucleotide resolution
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that require distinctive experimental protocols for achieving
optimal results (Chervitz et al., 2011). To improve the
data interoperability, comparisons of the epigenetics profiling
techniques have been initiated by the international consortia.
For example, the BLUEPRINT consortium has conducted a
systematic comparison of different DNA methylation profiling
technologies and reported generally consistent results, whilst
also highlighting the higher performance of sequencing-based
assays over array-based or antibody-based assays (BLUEPRINT
Consortium, 2016). Moreover, informatics approaches such
as APIs (Application Programming Interfaces) have been
developed to extract data from different repositories in a
more efficient manner. One example is the DeepBlue web
server, which provides an API for retrieving major epigenetic
studies of IHEC (Albrecht et al., 2016). The use of resource
description framework (RDF) such as Bio2RDF has also
been proposed to allow for the sharing of knowledge to
facilitate text mining techniques for information retrieval
(Jupp et al., 2014).
STATISTICAL AND DATA INTEGRATION
METHODS FOR INTERROGATING THE
EPIGENOME
As is the case in association studies in other fields, EWAS
detect epigenetic marks associated with a certain phenotype.
Common epigenetic study designs include case-control studies,
TABLE 3 | Epigenetic data repositories and browsers.
Consortia and resources Data availability URLs
The International Human Epigenome
Consortium (IHEC)
Reference epigenomes generated by NIH Roadmap,
ENCODE, CEEHRC, BLUEPRINT, DEEP,
AMED/CREST, and KEP
IHEC Data Portal http://epigenomesportal.ca/ihec
NIH Roadmap Epigenomics Maps of histone modifications, chromatin accessibility,
DNA methylation and mRNA Expression in stem cells
and primary ex vivo human tissues
VizHub http://vizhub.wustl.edu
Canadian Epigenetics, Environment and Health
Research Consortium (CEEHRC) Network
Reference epigenomes including histone modifications,





BLUEPRINT Epigenome Reference epigenomes of human normal and malignant
hematopoietic cells
BLUEPRINT Portal http://blueprint-data.bsc.es
The German epigenome programme (DEEP) Reference epigenomes of human cells and tissues in
normal and complex disease states
DEEP Data Portal http://deep.dkfz.de
IHEC Team Japan (AMED-CREST) Reference epigenomes of human gastrointestinal
epithelial cells, vascular endothelial cells and cells of
reproductive organs
IHEC Data Portal http://epigenomesportal.ca/ihec
Korea Epigenome Project (KEP) Reference epigenome map for common complex
diseases
IHEC Data Portal http://epigenomesportal.ca/ihec
DeepBlue Epigenomic data server for storing and working with
genomic and epigenomic data. Collection of over
30,000 experiment files from the main epigenome
mapping projects available. Uploading own data
allowed
DeepBlue server http://deepblue.mpi-inf.mpg.de
Allelic Epigenome Project Allelic DNA methylome, histone modifications, and
transcriptome in human cells and tissues
Genboree http:
//genboree.org/genboreeKB/projects/allelic-epigenome
GTEx Genotype and expression profiles in different tissues
enabling eQTL studies
GTEx Portal http://www.gtexportal.org
BRAINEAC Brain eQTL Almanac provides genotype and expression
profile across 10 brain regions
BRAINEAC http://braineac.org
MQTLdb Methylation and genotype data on mother-child pairs
providing access to meQTL mapping across five
different stages of life
mQTL Database http://www.mqtldb.org




Pancan-meQTL Database of cis- and trans- meQTLs across 23 cancer
types from The Cancer Genome Atlas
Pancan-meQTL
http://bioinfo.life.hust.edu.cn/Pancan-meQTL








Ensembl ENCODE data used in the regulatory build Ensembl ENCODE https://www.ensembl.org
RMBase Database listing over 100 RNA modifications http://rna.sysu.edu.cn/rmbase/
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cross-sectional or longitudinal cohort studies, and family or twin
designs. Logistic regression is commonly used for a case vs.
control or binomial phenotype design, while linear regression is
employed with continuous phenotypes. Technical and biological
covariates are added to the regression models to adjust for
confounding factors in the data and methods that control the false
discovery rate posed by multiple testing are applied.
The resulting epigenetic profiles can be visualized on
appropriate web tools, such as UCSC Genome Browser (Kent
et al., 2002), EpiGenome Browser (Zhou X. et al., 2011), or
coMET (Martin et al., 2015). While recent advances in epigenetic
profiling techniques have made EWAS more cost-efficient and
effective, interpreting the results from such epigenomic studies
remains a challenge. Without a careful selection of tissues
and population samples, many EWAS associations may partly
stem from the dynamic and complex nature of the interactions
between the different epigenetic layers, or arise from the fact
that epigenetic states differ spatially across tissues and cell types
as well as during aging. Therefore, there have been significant
difficulties inferring the causality of epigenetic marks among a
range of genetic, environmental and stochastic factors. A variety
of data integration approaches, such as co-mapping and network
analysis are currently employed to unravel the complexities of
these various epigenetic layers and their interaction with other
omics datasets (Hasin et al., 2017).
In this section we discuss data integration approaches for the
functional annotation of trait-associated epigenetic hits by the
use of knowledge bases, by predicting chromatin states, and by
establishing associations with gene expression. Alternatively, the
genetic basis of DNA methylation marks can be studied using the
meQTL analyses, from which computational tools can be utilized
to further identify the potential functional variants. The results
of robust associations between genetic variants, epigenetics
marks and disease traits can be integrated in the framework of
causal modeling, with an aim to dissect causal epigenetic marks
from those that are secondary to disease progression. These
likely causal epigenetic marks may be further developed into
potential disease biomarkers and drug targets upon experimental
investigation, for example using epigenome editing techniques.
Functional Annotation
Pathways
Genes and their regulators do not function in isolation,
but are organized into pathways and networks. To obtain a
more holistic view on the potential functional implications
of the EWAS hits, multiple tools on gene ontologies (GOs),
pathway and network analysis are available for researchers to
interpret their findings. For example, GO biological process,
molecular function, and cellular component pathways of the
EWAS hits can be explored by PANTHER (protein annotation
through evolutionary relationship) tools (Mi et al., 2013). Other
commonly used tools include Gene Set Enrichment Analysis
(GSEA) (Subramanian et al., 2005), where a predefined set of
genes represent a pathway collected from multiple databases
such as KEGG (Kyoto Encyclopedia of Genes and Genomes)
(Kanehisa et al., 2017). The commercial Ingenuity Pathway
Analysis (IPA© QIAGEN) can be also used to examine biological
networks, functions, and associated diseases (Kramer et al.,
2014). In addition to these gene centered analyses, genome
region enrichment analysis has been proposed to infer the
functional significance of the epigenetic marks at potential
regulatory elements. For example, the LOLA tool can test a
non-coding genomic region of interest for overlap with curated
region set databases (Sheffield and Bock, 2016). The GREAT tool
(Genomic Regions Enrichment of Annotations Tool) associates
cis-regulatory regions identified by, e.g., ChIP-seq with biological
processes by computing the enrichment scores for a given
ontology term of the nearby genes (McLean et al., 2010). As
a result, insights into the functional significance of the cis-
regulatory regions across the genome are produced.
Chromatin States
To infer the chromatin states from epigenetics data, network-
based methods such as hidden Markov model (HMM) have been
developed to determine the probability of chromatin states at
different genomic regions from the histone modification marks
(de Pretis and Pelizzola, 2014). Notably, a widely applied method
is ChromHMM which can efficiently learn the hidden chromatin
states based on the distinctive combinatorial and spatial patterns
of histone modification marks (Ernst and Kellis, 2017). These
data-driven chromatin states are then annotated by their
putative functions, such as transcription start sites, enhancers
or promoters. Annotating the genome with such predicted
chromatin states together with other genomic information may
reveal functional elements, particularly for those regions that
are in linkage disequilibrium (LD) with disease-associated SNPs.
ChromHMM has been implemented in an ENCODE study to
integrate 14 epigenetic marks, including histone modifications,
transcription factors and chromatin accessibility for 6 human
cell types, resulting in 25 chromatin states that are predictive
of RNA transcription (Hoffman et al., 2013). The resulting
gene regulatory elements mapped by these computational
methods from ENCODE and other consortium projects have
allowed individual researchers to interrogate and interpret
their EWAS findings. Furthermore, computational methods that
aim to predict tissue or cell-type specific functional regions
have been proposed. For example, a web-based tool eFORGE
(experimentally derived Functional element Overlap analysis
of ReGions from EWAS) can be used to inform which trait-
associated methylation hits are likely functional in a given tissue
or cell type. The eFORGE method computes an enrichment score
based on the overlap between the CpG sites of interest and DNase
I hypersensitive sites (as marks for active chromatin) to predict
the functionality of a CpG site in a given cell type, and thus
help prioritize the EWAS results in terms of functional impact
(Breeze et al., 2016). Another complementary method called
dCMA is based on differential chromatin modification analysis
to identify cell-type specific regulatory elements from ChIP-Seq
data (Chen et al., 2013).
Gene Expression
The association between epigenetic marks and gene expression
has been extensively studied to identify the functional
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consequences of epigenetic marks identified in an EWAS.
This is commonly accomplished by linear regression models
with the expression level of a gene as the dependent variable and
CpG site methylation or histone modification as the independent
variable. Adjusting for biological and technical confounders is
also common practice in such models, which can be used to
explore how epigenetic marks interact with gene expression
throughout the genome. For example, a recent study in human
blood cells applied a linear mixed effects model, by which DNA
methylation signatures for more than 13k transcripts were
defined (Kennedy et al., 2018).
While the association between CGI promoter methylation
and gene expression is well-established and readily interpretable
(Cedar and Bergman, 2012), the regulatory role of DNA
methylation outside CGIs, in ‘shores’ and ‘shelves’ and
throughout gene bodies is less extensively studied. However,
methylation in these regions is potentially more relevant to
diseases, as these are the regions that vary the most between tissue
types and between cancerous and normal tissue (Irizarry et al.,
2009). Unlike promoter methylation which is associated with
gene repression, the association between intragenic methylation
and gene expression is more bell-curved, with high methylation
associated with moderately expressed genes and low methylation
observed in genes with either high or low expression (Jjingo et al.,
2012). This complex relationship between DNA methylation
and gene expression poses challenges for comprehensively
integrating gene expression and DNA methylation data. Public
databases such as the Gene Expression Omnibus (GEO2) can also
be employed to assist in the interpretation of EWAS findings.
Inferring causal relationships between DNA methylation and
gene expression can be obtained by including genetic data in the
models, as discussed in the next two sections.
Identification of Genetic Drivers of
Epigenetic Marks
One of the major objectives in epigenetic studies is to identify
SNPs that are associated with DNA methylation marks as
meQTLs. In order to demonstrate whether trait-associated
DNA methylation is independent of genetic variants influencing
methylation, a regression analysis can be conducted using for
example R package MatrixEQTL (Shabalin, 2012). Results of
meQTL analyses include a ranked list of both short distance
cis and more distal (>1 Mb from the DNA methylation site)
trans effects of genetic variants on DNA methylation. Public
repositories such as the mQTLdb database (Gaunt et al., 2016)
and BIOS QTL browser (Bonder et al., 2017) are invaluable
in epigenetic research as they enable the results from large-
scale individual studies to be incorporated in subsequent meta
analyses. Recently, meta-databases have been developed to
systematically curate, harmonize and integrate meQTL data
across different diseases. For example, Pancan-meQTL provides
the result of meQTLs for 23 cancer types (Gong et al., 2018).
The findings of meQTL analyses can be coupled with eQTL
results in interpreting GWAS hits, as demonstrated in a recent
study which identified a strong correlation between meQTLs
2https://www.ncbi.nlm.nih.gov/geo/
and eQTLs that are shared by common genetic variants from
peripheral blood (Pierce et al., 2018). Similar conclusions have
been made in a study involving 3,841 Dutch individuals, where
disease-associated variants have been found to affect both
transcription factor levels and methylation of their binding sites
(Bonder et al., 2017).
Integrating epigenetic marks with genotypes can also aid in
interpreting the functionality of trait-associated SNPs observed in
GWAS. Therefore, computational tools to predict the functions
of genetic variants can be also used for annotating the
functional consequences of meQTLs. Information that has been
generally considered in such prediction tasks includes sequence
conservation, population frequency as well as functional
genomics. Approaches such as SIFT (Kumar et al., 2009) and
PolyPhen2 (Adzhubei et al., 2013) align human protein sequences
to homologous sequences from the other organisms to evaluate
the impact of missense variants. Such sequence conservation
approaches have been extended to identify conserved elements
in non-coding regions by PhastCons (Siepel et al., 2005) and
GERP (Davydov et al., 2010). In comparison, tools such as
VAAST also utilize population frequency information from
large consortiums, i.e., the 1000 Genome project for variant
prioritization. Moreover, machine learning technology has long
been introduced into the functional annotation of genetic
variants (see Holder et al., 2017 for a recent review). For
example, the PANTHER method utilizes a HMM to capture
the relationship between sequence similarity and functional
similarity, based on which the functional impact of a given
genetic variant can be predicted (Thomas et al., 2003). As one
of the most widely used methods, the CADD method employed
epigenomic information such as genomic regions of DNase I
hypersensitivity and histone modifications as predictive features
to train the Supported Vector Machine to predict the causal
variants in the genomic regions (Rentzsch et al., 2019).
Dissecting Causality by Mendelian
Randomization and Causal Networks
While many of the above-mentioned methods help illustrate
the various functions of trait -associated epigenetic marks, it
is often difficult to distinguish cause from consequence. In
addition, the associations are often confounded by other factors.
Mendelian randomization (MR) is a special form of causal
network modeling, where the causality between a potential risk
factor and an outcome can be established by including the
genotype data (Tang et al., 2009; Latvala and Ollikainen, 2016).
To be able to establish whether an association between an
epigenetic mark and a disease outcome is causal, MR utilizes a
series of statistical inference rules, which start by identifying an
instrumental variable from the trait-associated genetic variants.
This genetic instrument must fulfill the following criteria: (1)
associated with the exposure, (2) independent of any potential
confounders, and (3) associated with the outcome of interest only
via its association with the exposure. Since the genetic variant
occurs at germline that precedes the onset of disease, reverse
causality is not possible. Also, as parental alleles are randomly
segregated and assorted to offspring, associations between genetic
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variation and the outcome of interest are unlikely to be affected by
confounding factors. The principles and recent developments in
MR are described in detail elsewhere (Davey Smith and Ebrahim,
2003; Davey Smith and Hemani, 2014).
Mendelian randomization has been commonly used in
epidemiology, and has recently been applied to infer causality
in epigenetics studies as well. Depending on the applications,
epigenetics marks have been considered as either the exposure
or the outcome of interest in the MR model. For example, Relton
and Davey Smith provided a two-step MR framework to select
the instrument variables for both the risk factors and the DNA
methylation marks, so that the causality cascade from the risk
factors to the disease outcome can be established (Relton and
Davey Smith, 2012). Such a two-step MR framework has been
recently applied to study the causal roles of DNA methylation
between smoking and inflammation (Jhun et al., 2017). On the
other hand, a similar stepwise MR framework has been applied
to distinguish causal effects from associations between blood
lipid levels and DNA methylation, where the blood lipid levels
were considered as the risk factor to affect DNA methylation
of white blood cells (Dekkers et al., 2016). More recently,
a systematic MR study involved multiple steps to investigate
the meQTLs as the instrumental variables to understand the
causal effect of DNA methylation for a large variety of disease
traits (Richardson et al., 2018). As a validation, majority of the
candidate loci were known to affect gene expression and DNA
methylation, and thus supported the validity of MR as a data-
driven approach to generate plausible biological hypotheses that
warrant further experimental investigation. The basic version
of MR involves the use of bivariate analysis, which can be
extended as a causal network inference that involves the testing
of multiple instrument variables in relation to different risk
factors and disease outcomes. For example, the joint likelihood
method (JLIM) tests whether two risk factors share the same
causal genetic variants by evaluating the similarity of LD patterns
between the SNPs, which is a form of co-localization methods
(Chun et al., 2017). The other co-localization methods include
HEIDI (heterogeneity in dependent instrument) (Zhu et al.,
2016) and coloc (Giambartolomei et al., 2014) methods, while
only summary-level data is used. More recently, a method
called GSMR leveraged multiple SNPs as instrument variables
to test for causality between risk factors and common diseases
(Zhu et al., 2018).
Alternatives of causal modeling include the causal mediation
analysis, which employs a series of hypothesis testing on the
conditional independence among genetic variants, exposure, and
disease traits (Millstein et al., 2009). The mediation analysis
infers how much the indirect causal effect of an exposure on a
disease outcome is mediated by a mediator, while MR focuses on
the direct causal effect of the exposure on the disease outcome
using a genetic variant as the proxy (Richmond et al., 2016a).
A model-based causal mediation approach is available in the
mediation R package (Imai et al., 2010), which has been applied
in a recent study to identify nine potential epigenetic CpG sites
that may mediate the effect of prenatal famine exposure to adult
body mass index (BMI), serum triglycerides, and glucose levels.
Notably, these CpG sites were all located at regulatory regions
which are linked to the expression of growth, differentiation, and
metabolism-related genes (Tobi et al., 2018).
For a model selection perspective, both causal mediation
analysis and MR can be considered as special cases of causal
network modeling, which compares the likelihoods for multiple
competing models about causality (e.g., reverse causality model
or confounding effect model) (Burgess et al., 2015). These
different statistical frameworks to test for causality of epigenetic
marks are useful tools, however, it is never possible to definitively
prove causality based on these methods only. Instead, any
negative or positive findings should be interpreted with caution
and should be supported by multiple independent approaches
with different assumptions, as well as the sensitivity analyses of
the measurement error, and finally to match with the available
biological knowledge and experimental validation (Hermani
et al., 2017; Yarmolinsky et al., 2018).
INTEGRATIVE APPROACHES TO
UNDERSTAND THE ROLE OF
EPIGENETICS IN COMPLEX TRAITS
To date, 10s of 1000s of genetic variants have been associated with
human complex traits via GWAS. Based on the findings of twin
studies, these diseases and traits are, on average, 50% heritable
(Polderman et al., 2015). To be able to better explain the functions
of the genetic variants, the field of epigenetics has been actively
researched. Next, we will describe a few representative case
studies in obesity and cancer, where the integration of genetic,
epigenetic, and transcriptomic data has been a key component
in understanding the disease etiology and progression. The
information gained from such studies can then help inform
future diagnostic biomarker and treatment strategies.
Obesity and Associated Traits
Numerous EWAS studies have shown that BMI and obesity are
associated with widespread changes in DNA methylation, most
often profiled using Illumina 450K or EPIC arrays (Dick et al.,
2014; Ollikainen et al., 2015; Pietilainen et al., 2016; Mendelson
et al., 2017; Wahl et al., 2017; Davis et al., 2018; Dhana et al.,
2018). Most of the findings are tissue specific, or shared by a few
tissue types (Dick et al., 2014; Wahl et al., 2017), with some hits
replicated between studies, while others appear to be more study
or population specific. Many of the observed DNA methylation
hits are at or near genes that have previously been related to BMI
or obesity traits by genetic association, while others may reflect
novel genes and pathways involved in the regulation of adiposity
or obesity-related diseases (Ollikainen et al., 2015; Mendelson
et al., 2017; Wahl et al., 2017).
Integration of DNA methylation data with predicted
chromatin states from ENCODE data has revealed that the
genomic regions associated with obesity by DNA methylation
are often enriched for regulatory features (Ollikainen et al., 2015;
Wahl et al., 2017). Potential functional consequences of the
observed methylation alterations have been tested by correlating
DNA methylation with gene expression of the nearby genes, and
concomitant changes in DNA methylation and gene expression
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have been observed in many obesity relevant genes. Integration
of DNA methylation with genotype data (as meQTLs) has been
used to annotate GWAS hits, and to identify novel candidate
obesity-associated genes. For example meQTLs at KLF13 (Koh
et al., 2017) and MCR4 (Tang et al., 2017) have been shown to
associate with childhood obesity. In addition to identification of
meQTLs, integration of genotypes and DNA methylation can be
used to infer causality in the observed associations, for example
by MR –based approaches. These analyses have shown that the
observed associations are predominantly the consequence of
high BMI or obesity – related metabolic outcomes (Dick et al.,
2014; Ollikainen et al., 2015; Richmond et al., 2016b; Wahl
et al., 2017). However, NFATC2IP and SREBF1 methylation
have been shown to have potential causal associations with BMI
(Mendelson et al., 2017; Wahl et al., 2017). Finally, some studies
have shown that the disturbances in DNA methylation predict
future development of type 2 diabetes (Wahl et al., 2017) and
coronary heart disease (Hedman et al., 2017), and that DNA
methylation could be used to distinguish metabolically unhealthy
from healthy obesity (Ollikainen et al., 2015; Wahl et al., 2017).
To enable early detection of individuals with increased risk
for metabolic complications, further studies are needed to
thoroughly examine whether DNA-methylation could serve as a
biomarker for metabolically unhealthy obesity.
Taken together, results from multiple epigenetic studies using
data integration approaches in obesity and related traits may
provide new insights into the biological pathways influenced
by adiposity. Although most of the epigenetic changes are
consequential to obesity or related traits, a few appear to have
a causal role. Identification of causal hits is critical not only for
understanding the biological mechanisms in the development
of obesity and metabolic disturbances, but also for developing
novel, effective prevention, and treatment strategies that target
the underlying mechanisms. However, the cross-sectional nature
of most of the analyzed data sets limits definitive causal
determination. In addition, the marks that are caused by obesity
can be considered as potential biomarkers of obesity or related
metabolic disturbances. These may enable development of new
strategies for prediction and prevention of adverse metabolic
consequences of obesity.
Cancer
Despite the fact that cancer has been traditionally perceived as
a genetic disease, epigenetic mechanisms have been increasingly
identified to contribute to many hallmarks of cancer (Flavahan
et al., 2017). Epigenetic alterations are shown to be responsible for
the activation of cancer oncogenes or the inactivation of tumor
suppressors (Kagohara et al., 2018). Numerous recent cancer
epigenetics studies have demonstrated that data integration
not only enables a more detailed understanding of disease
mechanisms at the molecular level, but also offers novel insights
on improved approaches for disease diagnostics, treatment, and
management. For example, The Cancer Genome Atlas (TCGA)
project has produced DNA methylation data for over 10000
cancer samples (Hoadley et al., 2014). Here, we highlight a few
representative cancer epigenetic studies where a combination of
multiple data analysis methods have been applied.
One case study implemented a genome-wide chromatin
accessibility profiling for chronic lymphocytic leukemia (CLL)
patient samples using ChIPmentation and RNA-seq profiling
(Rendeiro et al., 2016). Using a Random Forest machine learning
method (Rahman et al., 2017), it was found that epigenetic
profiles can accurately predict the IGHV mutation status.
Furthermore, common and constitutively accessible regions as
well as regions with higher inter-individual variability were also
found. Similar studies were done using reduced representation
bisulfite sequencing (RRBS) for Ewing sarcoma, a rare cancer that
is known to be caused by the EWS-FLI1 fusion gene. Despite
the common genetic background, substantial DNA methylation
differences between and within cancers were found (Sheffield
et al., 2017). Notably, several computational tools have been
developed in this study. For example, a MIRA score has been
derived to transform the epigenetic state of a given genomic
region into the degree of regulatory activity. Moreover, the
intra-tumor heterogeneity has been measured using the PIM
(proportion of sites with intermediate methylation) and PDR
(proportion of discordant reads) scoring which can capture the
cell-to-cell heterogeneity and the epigenetic instability within the
tumor cells separately. The PIM score was then used to predict
the metastatic state of a patient-derive sample using a logistic
regression model.
Another study focused on triple-negative breast cancer
(TNBC) by jointly contrasting the transcriptomic and epigenetic
profiles of cancer stem cells (CSCs) versus non-cancer stem
cells (NCSCs) (Li et al., 2018). Differentially expressed genes
between CSCs and NCSCs were first identified by performing
an RNA-Seq data preprocessing using tools including HTSeq
(Anders et al., 2015) and samtools (Li et al., 2009), as well
as differential analyses using R packages including DEGSeq
(Wang et al., 2010). Subsequently, functional significance of cis-
regulatory regions were analyzed with the GREAT (McLean et al.,
2010) for the identification of significantly disrupted signaling
pathways. Furthermore, patterns of differential DNA methylation
and histone modifications were analyzed. By performing a
WGBS analysis, differentially-methylated CpG sites in promoter
regions [defined around genes’ transcription start sites (TSSs)]
were identified using the methylKit R package (Akalin et al.,
2012) and PeakAnalyzer (Salmon-Divon et al., 2010). In parallel,
histone modifications were analyzed using ChIP-seq to determine
and visualize different binding sites of antibodies specific to
H3K4me2 (considered as a permissive mark for transcription)
and H3K27me3 (a transcriptional silencer), using the R packages
DiffBind (Ross-Innes et al., 2012) and seqMINER (Zhan and Liu,
2015). As a result, the repressive mark H3K27me3 appeared to
contribute more to the tumor-promoting tendencies of CSCs,
notably by affecting melanogenesis, Wnt, and GnRH pathways,
all of which are known to be involved in cellular proliferation and
self-renewal, conferring to the typical characteristics of chemo- or
radiotherapy- resistance.
In a study conducted on epithelial ovarian cancer (EOC), the
integrated analysis of genetic (GWAS), expression (proteomic)
and epigenetic (DNA methylation) data permitted the
identification of a novel subtype-specific susceptibility gene for
the malignancy (Shen et al., 2013). As a first step, a GWAS study
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for ovarian cancer (consisting of 43 smaller studies and a total of
more than 16,000 EOC patients) identified various HNF1B SNPs
for the serous and the clear cell subtypes of EOC. Specifically,
while rs7405776 [minor allele frequency (MAF) = 36%] was the
most strongly associated SNP with serous EOC and conferred an
increased risk of 13% per minor allele, rs11651755 (MAF = 45%)
was strongly associated with the clear cell subtype of EOC
and decreased the malignancy risk by 23% at genome-wide
significance. This detection of HNF1B as a risk gene encouraged
a more detailed evaluation of its promoter methylation profiles
and its proteomic expression levels. An epigenetic silencing
of HNF1B by DNA methylation was confirmed in half of the
cases in the TCGA data including 576 primary serous EOC
samples. To follow-up on the functional effects of the retained
DNA methylation, a third cohort of 1149 EOC samples from the
Ovarian Tumor Tissue Analysis (OTTA) Consortium (Bolton
et al., 2012) was assessed. DNA-methylation analysis was also
performed on 254 serous cases and 17 clear cell cases from those
samples, using the Illumina 450K assay, with plate normalization
using a linear model on the logit-transformed beta values. The
correlation between the gene expression and methylation was
in line with the previous hypotheses, revealing a high HNF1B
expression and absence of promoter-methylation in most of the
clear cell EOV samples, while the majority of serous samples
displayed high promoter-methylation and stained negative for
HNF1B in the IHC assay. Such an integrated analysis involving
multiple omics data provides strong evidence that different
genetic or epigenetic variations within the HNF1B gene can
predispose to different histological variants of EOV, and that
those variations could potentially be used as diagnostic tools for
ovarian tumors.
Epigenetics Biomarker and Drug
Discovery
Upon the validation of its functional role in the disease etiology,
an epigenetic mark can be further developed as a diagnostic
biomarker or a drug target. By definition, a biomarker is
any characteristic that can be quantified and evaluated as an
indicator of normal or pathogenic biological processes, or as
a measure of response to some form of treatment. Biomarkers
can take a wide variety of forms, including (but not limited
to) genomic modifications, RNA transcripts, proteins, and/or
epigenetic alterations (Costa-Pinheiro et al., 2015). Ideally,
a suitable biomarker is a highly accurate one that can be
obtained in a minimally invasive or non-invasive manner,
which can be utilized for screening and detection methods,
diagnosis and prognostication purposes, risk assessment, and/or
for the prediction of response to therapy. Accordingly, epigenetic
changes are considered among the most promising classes of
cancer biomarkers, owing to their stability, potential reversibility,
and ease of access. There are a few epigenetic biomarkers
approved in non-invasive cancer diagnosis. For example,
Cologuard has become the first FDA approved test for colorectal
cancer (CRC) which involves the testing of DNA methylation
levels at BMP3 and NDRG4, together with the mutation status
of KRAS and hemoglobin. More recently FDA has approved a
blood-based screening test for CRC called Epi procolon. The test
measures the DNA methylation level of SEPT9, a gene that has
been found to be hypermethylated in the promoter region (Issa
and Noureddine, 2017).
Currently, a rich set of epigenetic biomarkers, including non-
coding RNA expression levels, aberrant methylation patterns, and
histone-modifying enzyme levels, are being tested in preclinical
and clinical settings. For example, a urine-based epigenetic test
on the DNA methylation of three genes (TWIST1, ONECTU2,
and OTX1) in bladder cancer has achieved superior accuracy and
now progressed to a larger validation study (Velazquez, 2018).
Other potential epigenetic biomarkers include SHOX2 for lung
cancer and BRCA1 for breast and ovarian cancers (Fece de la
Cruz and Corcoran, 2018). To be able to leverage the existing
cancer samples in the TCGA, a recent study developed a pan-
cancer bisulfite sequencing assay to measure the methylation
status of 9,223 GpG sites in plasma cell-free DNA in 34 major
cancer types (Liu et al., 2018). The derived methylation signatures
were then used for training a cancer type -specific classifier,
each of which consisted of a unique set of CpG sites. The
resulting classifier was used to predict the cancer type for a given
sample, based solely on its methylation signature, demonstrating
the feasibility of genome-wide epigenetic profiles for cancer
diagnosis. In contrast, the development of epigenetics biomarkers
in other disease areas is relatively in its early stage, with a few links
being made for diabetes (Bacos et al., 2016) and schizophrenia
(Rodrigues-Amorim et al., 2017).
In epigenetic drug discovery, histone post-translational
modifications (PTMs) have been pursued as a major strategy
as they constitute one of the most immediate contributors
to epigenetic regulation. The PTM-affecting enzymes can be
classified into three distinctive functional classes including
writers, erasers and readers, which have been pursued as the
targets for epigenetic drugs (Hyun et al., 2017). For example,
cancer epigenetic therapy has focused on the development
of targeted histone deacetylase (HDAC) inhibitors and DNA
methyltransferase (DNMT) inhibitors. HDAC inhibitors activate
histone acetylation, leading to higher expression of certain genes
for apoptosis and cell cycle, while DNMT inhibitors re-activate
tumor suppressor genes. The use of HDAC (e.g., vorinostat,
belinostat, panobinostat, and romidepsin) and DNMT inhibitors
(e.g., azacytidine and decitabine) has been approved for
hematological malignancies. Furthermore, combinations of
HDAC and DNMT inhibitors have shown synergistic interactions
in a variety of cancer cell lines (Brocks et al., 2017).
In addition, overexpression and activity of histone
methyltransferases (HMT) have been reported in a variety
of cancers, notably acting via the silencing of essential tumor-
suppressors (Bracken et al., 2003; Kim and Roberts, 2016).
Consequently, HMT inhibitors such as tazemetostat and
CPI-1205 have found their way to clinical development. It is
unlikely that any single drug targeting epigenetic modifications
is capable of curing a malignancy on its own. The combination
with other such drug or with standard chemotherapeutic
approaches offers the most promising prospects. For example,
DNMT and HDAC inhibitors are thought to open up
the chromatin conformation, thus rendering DNA more
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accessible to, and thereby more susceptible to damage, by
chemotherapy. This observation has been validated by the
successful combinations of azacitidine and low-dose cytarabine
for AML (Radujkovic et al., 2014), or those of vorinostat
and carboplatin or paclitaxel in non-small cell lung cancer
(Owonikoko et al., 2010).
Other epigenetic modifiers that target the downstream
proteins also have sparked interest. For example, the family of
bromodomain containing proteins known as BETs have been
involved in chromatin remodeling and transcriptional activity
in a variety of diseases including inflammation, viral infection
and cancer (Ferri et al., 2016). Furthermore, BET inhibition has
been shown to decrease MYC expression and to restore normal
cellular functions in a variety of cancers including hematological
malignancies and solid tumors (Wang and Filippakopoulos,
2015). The first potent and selective BET inhibitor is the thieno-
tiazolo-1,4-diazepine, known as the positive enantiomer (+) of
JQ1. Other BET inhibitors include I-BET762 which is currently
being investigated in several ongoing clinical trials for different
cancers (Andrieu et al., 2016).
Pharmacoepigenetics
Due to the lack of full annotations on the drug-induced
epigenetic changes, the exact mode of action of the epigenetic
drugs in different cancer cells remains largely unknown, which
partly explains the individual variation in the clinical response
(Treppendahl et al., 2014). On the other hand, it has been
shown that many common drugs also induce epigenetic changes
via the direct interaction with the PTM-affecting enzymes, or
the downstream drug signaling pathways (Lotsch et al., 2013).
These epigenetic changes may contribute to both the therapeutic
and the adverse effects of the compounds, which are also
mediated by the patient’s individual genetic background, e.g.,
of drug-metabolizing enzymes and transporters. Only recently
the concept of pharmacoepigenetics has started to emerge,
aiming at the study of epigenetic mechanisms to explain the
interindividual variability in drug responses (Majchrzak-Celińska
and Baer-Dubowska, 2017; Lauschke et al., 2018). The epigenetic
regulators of drug responses have been often linked to ADME
(drug absorption, distribution, metabolism, and excretion) genes.
For example, many genes in the Cytochrome P450 family are
reported to be directly or indirectly regulated by miRNAs (Kim
et al., 2014). Hypomethylation of the ABCB1 promoter region
has been shown to increase the gene’s expression in cancer cells,
leading to acquired drug resistance (Reed et al., 2010). Research
in this field may eventually lead to the development of ADME-
related biomarkers for the stratification of patients into different
treatment groups. In addition, epigenetic biomarkers that are
not linked to ADME genes were also reported, while the exact
mechanisms remain largely undetermined. In breast cancer for
example, the quantification of PSAT1 DNA methylation is used
to predict tamoxifen response (Martens et al., 2005; De Marchi
et al., 2017), whereas that of BRCA1/2 (similarly to somatic
mutations in those genes) is indicative of response to PARP
inhibitors (Martens et al., 2005). Similarly, hypermethylation
of MGMT and MLH1 correlates with increased response to
5-FU treatment and improved survival in CRC (Nagasaka
et al., 2003; Jensen et al., 2013). Notably, a recent clinical
study has discovered a DNA methylation signature to predict
the response of Anti-Programmed Death-1 (PD-1) treatment
for advanced non-small-cell lung cancer (Duruisseaux et al.,
2018). Another clinical study called Genetic and Environmental
Determinants of Triglycerides (GOLDN) measured the genetic
and epigenetic profiles for metabolic syndrome using a family-
based design (Aslibekyan et al., 2018). In this study, the
epigenetic profiling was made before and after the treatment
of fenofibrate, allowing the characterization of genotype and
DNA methylation to understand the variability in the drug
treatment response. Despite that potential biomarkers have
been found in these recent advances, a systematic strategy
to predict and understand the epigenome-wide interactions
mediating the drug responses is still lacking. We anticipate
that data integration methods as summarized in previous
sections that are capable of annotating the epigenome from a
pharmacological and pharmacokinetic perspective shall provide
a valuable source of information to inform personalized
treatment decisions.
CONCLUSION
Understanding epigenomic regulation is critical for dissecting
gene–environment interactions in both normal development
and disease. The fact that epigenetic profiles are plastic
and reversible holds great promise for developing epigenetic
biomarkers and drug targets. Furthermore, epigenetics captures
the spatial and temporal variation on top of each individual’s
unique genome, and thus better informs the decision-making
in personalized medicine. Recent developments have made
chromatin accessibility profiling more cost-effective by allowing
only a small number of cells as input, demonstrating the
clinical potential of disease monitoring (Buenrostro et al., 2015).
On the other hand, biobanks have made large scale clinical
samples accessible and often provide functionality to share
the accumulating raw data and molecular profiles similar to
the concept of European Genome-Phenome Archive (EGA)
(Lappalainen et al., 2015). Although individual epigenetic marks
are often studied in isolation, the understanding of how the
putative gene regulatory mechanisms occur will not be achieved
without efficient tools to design, analyze, integrate, and interpret
the versatile epigenetic features. To facilitate the systematic
characterization of cells in a specific context, the other omics
data such as transcriptomics and metabolomics may also provide
complementary information to explain the interplay of the
gene–environment interaction. Further developing the data
integration tools shall more efficiently prioritize robust epigenetic
modifications that are susceptible to environmental exposures
and causal to specific diseases, so that specifically targeted
compounds can be developed. Furthermore, despite the advances
in these computational methods, one needs to ultimately resort to
experimental approaches to confirm the hypothesis. The recent
development of CRISPR-Cas9 and other genome editing tools
may provide an efficient way to induce epigenetic alterations
without the change of DNA sequences, so that novel drug targets
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and disease biomarkers may be identified more efficiently
(Liao et al., 2017).
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